Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918922 | 0.89 | CYP2C8 (0.53) | CYP3A4CYP2C8KCNH2NR1I2ANO1 | |
| SCHEMBL143697 | 0.89 | CYP2C8 (0.55) | CYP3A4CYP2C8KCNH2NR1I2ANO1 | |
| SCHEMBL1918814 | 0.87 | CYP2C8 (0.50) | CYP3A4CYP2C8KCNH2NR1I2KDM4E | |
| SCHEMBL2140983 | 0.86 | CYP3A4 (0.42) | CYP3A4CYP2C8KCNH2NR1I2ANO1 | |
| SCHEMBL12240922 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2C8KCNH2NR1I2KDM4E | |
| SCHEMBL1918703 | 0.84 | CYP2C8 (0.55) | CYP3A4CYP2C8KCNH2NR1I2ANO1 | |
| SCHEMBL12159318 | 0.83 | CYP2C8 (0.54) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2142289 | 0.83 | CYP2C8 (0.54) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2141615 | 0.83 | CYP2C8 (0.68) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2139914 | 0.83 | CYP2C8 (0.58) | CYP3A4CYP2C8KCNH2NR1I2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | CYP3A4 299/4885CYP2C8 85/4885KCNH2 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.